Skip to main content
SpringerLink
Log in

Prospective study of combination therapy with low-dose thalidomide plus prednisolone ameliorating cytopenia in primary myelofibrosis

  • Letter to the Editor
  • Published:
International Journal of Hematology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Barosi G, Grossi A, Comotti B, et al. Safety and efficacy of thalidomide in patients with myelofibrosis with myeloid metaplasia. Br J Haematol. 2001;114:78–83.

    Article  CAS  PubMed  Google Scholar 

  2. Piccaluga PP, Visani G, Pileri SA, et al. Clinical efficacy and antiangiogenic activity of thalidomide in myelofibrosis with myeloid metaplasia. A pilot study. Leukemia. 2002;16:1609–14.

    Article  CAS  PubMed  Google Scholar 

  3. Marchetti M, Barosi G, Balestri F, Viarengo G, Gentili S, Barulli S, Demory JL, Ilariucci F, Volpe A, Bordessoule D, Grossi A, Le Bousse-Kerdiles MC, Caenazzo A, Pecci A, Falcone A, Broccia G, Bendotti C, Bauduer F, Buccisano F, Dupriez B. Low-dose thalidomide ameliorates cytopenias and splenomegaly in myelofibrosis with myeloid metaplasia: a phase II trial. J Clin Oncol. 2004;22:424–31.

    Article  CAS  PubMed  Google Scholar 

  4. Strupp C, Germing U, Scherer A, et al. Thalidomide for the treatment of idiopathic myelofibrosis. Eur J Haematol. 2004;72:52–7.

    Article  CAS  PubMed  Google Scholar 

  5. Abgrall JF, Guibaud I, Bastie JN, Flesch M, Rossi JF, Lacotte-Thierry L, Boyer F, Casassus P, Slama B, Berthou C, Rodon P, Leporrier M, Villemagne B, Himberlin C, Ghomari K, Larosa F, Rollot F, Dugay J, Allard C, Maigre M, Isnard F, Zerbib R, Cauvin JM, Groupe Ouest-Est Leucémies et Maladies du Sang (GOELAMS). Thalidomide versus placebo in myeloid metaplasia with myelofibrosis: a prospective, randomized, double-blind, multicenter study. Haematologica. 2006;91:1027–32.

    CAS  PubMed  Google Scholar 

  6. Thomas DA, Giles FJ, Albitar M, Cortes JE, Verstovsek S, Faderl S, O’Brien SM, Garcia-Manero G, Keating MJ, Pierce S, et al. Thalidomide therapy for myelofibrosis with myeloid metaplasia. Cancer. 2006;106:1974–84.

    Article  CAS  PubMed  Google Scholar 

  7. Mesa RA, Steensma DP, Pardanani A, et al. A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia. Blood. 2003;101:2534–41.

    Article  CAS  PubMed  Google Scholar 

  8. Tefferi A, Cortes J, Verstovsek S, Mesa RA, Thomas D, Lasho TL, Hogan WJ, Litzow MR, Allred JB, Jones D, Byrne C, Zeldis JB, Ketterling RP, McClure RF, Giles F, Kantarjian HM. Lenalidomide therapy in myelofibrosis with myeloid metaplasia. Blood. 2006;108:1158–64.

    Article  CAS  PubMed  Google Scholar 

  9. Quintás-Cardama A, Kantarjian HM, Manshouri T, Thomas D, Cortes J, Ravandi F, Garcia-Manero G, Ferrajoli A, Bueso-Ramos C, Verstovsek S. Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis. J Clin Oncol. 2009;27:4760–6.

    Article  PubMed  Google Scholar 

  10. Tefferi A, Verstovsek S, Barosi G, Passamonti F, Roboz GJ, Gisslinger H, Paquette RL, Cervantes F, Rivera CE, Deeg HJ, Thiele J, Kvasnicka HM, Vardiman JW, Zhang Y, Bekele BN, Mesa RA, Gale RP, Kantarjian HM. Pomalidomide is active in the treatment of anemia associated with myelofibrosis. J Clin Oncol. 2009;27:4563–9.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

We thank professors Yasuo Ikeda and Masahiro Kizaki for their help to conduct the clinical study. This work was partly supported by Keio Gijuku Academic development Funds (Y.H.), the Princess Takamatsu Cancer Research Fund (Y.H.) and Japan Leukemia Research Fund (Y.H.)

Author information

Authors and Affiliations

  1. Division of Clinical Physiology and Therapeutics, Faculty of Pharmacy, Keio University, 1-5-30, Shibakoen, Minato-ku, Tokyo, 105-8512, Japan

    Yutaka Hattori

  2. Division of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan

    Yoshitaka Miyakawa, Kenji Yokoyama & Shinichiro Okamoto

  3. Department of Pathology, Keio University School of Medicine, Tokyo, Japan

    Taketo Yamada & Wenlin Du

  4. Department of Diagnostic Radiology, Keio University School of Medicine, Tokyo, Japan

    Masahiro Jinzaki & Hiroshi Shinmoto

Authors
  1. Yutaka Hattori
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yoshitaka Miyakawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kenji Yokoyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Taketo Yamada
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Wenlin Du
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Masahiro Jinzaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Hiroshi Shinmoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Shinichiro Okamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yutaka Hattori.

About this article

Cite this article

Hattori, Y., Miyakawa, Y., Yokoyama, K. et al. Prospective study of combination therapy with low-dose thalidomide plus prednisolone ameliorating cytopenia in primary myelofibrosis. Int J Hematol 93, 129–131 (2011). https://doi.org/10.1007/s12185-010-0733-3

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12185-010-0733-3

Keywords

Search

Navigation